ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: SA-PO264

Effect of Sotagliflozin (SOTA) on Albuminuria in Patients With Type 2 Diabetes (T2D) and CKD

Session Information

Category: Diabetic Kidney Disease

  • 602 Diabetic Kidney Disease: Clinical


  • Cherney, David, Toronto General Hospital, Toronto, Ontario, Canada
  • Bhatt, Deepak L., Brigham and Women's Hospital, Boston, Massachusetts, United States
  • Szarek, Michael, University of Colorado Anschutz, Aurora, Colorado, United States
  • Sun, Franklin W., Lexicon Pharmaceuticals Inc, The Woodlands, Texas, United States
  • Davies, Michael J., Lexicon Pharmaceuticals Inc, The Woodlands, Texas, United States
  • Pitt, Bertram, University of Michigan, Ann Arbor, Michigan, United States
  • Steg, Philippe Gabriel, Hôpital Bichat, Assistance Publique - Hôpitaux de Paris, Paris, France

Group or Team Name

  • the SCORED Investigators

Albuminuria in patients with/without diabetes presents a higher risk for adverse renal and cardiovascular (CV) outcomes. SGLT inhibitors demonstrate improved albuminuria. The study observed the impact of the SGLT1/SGLT2 inhibitor SOTA on urine albumin-to-creatinine ratio (UACR).


SCORED—a Phase 3, multicenter, double-blind, placebo-controlled, parallel-group study—randomized 10,584 patients with T2D, CKD, and other CV risk factors to SOTA or placebo. Kidney inclusion criteria were eGFR 25-60mL/min/1.73m2 and any UACR. Percentage treatment difference was estimated by geometric mean ratio for the overall cohort and by eGFR and UACR subgroups. Progression/regression of UACR were assessed. Hazard ratios, 95% confidence intervals (CI), and p-values were estimated by Cox proportional hazards model.


Median baseline eGFR was 44.5mL/min/1.73m2, with 8% at <30mL/min/1.73m2. At baseline, median UACR was 82mg/g, and 1/3 of patients had normoalbuminuria, 1/3 had micro, and 1/3 had macro. Median follow up was 16 months. The UACR difference for SOTA vs placebo was -21.3% (95% CI -23.4, -19.1; p<0.0001). Reductions were similar across eGFRs. In UACR 30-299mg/g and ≥300mg/g, reductions were significant in SOTA (p<0.0001;Fig 1). Progression risk was lower and regression risk higher in SOTA vs placebo (p<0.0001;Fig 2).


SOTA significantly reduced UACR and had favorable effects on UACR progression and regression.


  • Commercial Support –